The first, 1C2, is a broadly neutralizing antibody directed to the gp41-gp120 interface region and neutralizes more than 80% of a panel of 40+ HIV strains.
Conclusions: We conclude that N-glycan-deleted trimer priming followed by heterologous boosting is a successful strategy to elicit bNAbs, validating an epitope-based approach independent of “germline targeting”, and the rabbit immune system that can generate bNAbs using completely different V(D)J building blocks compared to human. The implications of these exciting results are important as we move forward to clinical testing of relevant candidates toward a real-world vaccine.
Market Data 
Markets 
AI
